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Hepatitis C virus (HCV) infects approximately 170 million people worldwide and is a major
cause of life-threatening liver diseases such as liver cirrhosis and hepatocellular carci-
noma. Acute HCV infection often progresses to chronic persistent infection, although some
patients recover spontaneously.The divergent outcomes of acute HCV infection are known
to be determined by differences in virus-specific T-cell responses among patients. Of the
two major T-cell subsets, CD8+ T-cells are known to be the key effector cells that con-
trol viral infections via cytolytic activity and cytokine secretion. Herein, we review various
aspects of HCV-specific CD8+ T-cell responses in acute HCV infection. In particular, we
focus on timing of CD8+T-cell responses, relationship between CD8+T-cell responses and
outcomes of acute HCV infection, receptor expression on CD8+ T-cells, breadth of CD8+
T-cell responses, and viral mutations.
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INTRODUCTION
Hepatitis C virus (HCV) is a positive-stranded RNA virus of the
genus Hepacivirus in the family Flaviviridae that infects approxi-
mately 170 million people worldwide (1, 2). Acute HCV infection
is spontaneously cleared in 20–30% of patients; however, the
majority of patients fail to clear HCV and develop chronic per-
sistent infection, which tends to progress to life-threatening liver
diseases such as liver cirrhosis and hepatocellular carcinoma (3).
Typically, patients with self-limited acute HCV infection undergo
sustained viral clearance within the first 12 weeks of disease onset,
whereas viremia beyond 6 months generally indicates chronic evo-
lution (4). The divergent outcomes of acute HCV infection are
known to be determined by differences in virus-specific T-cell
responses among patients (5–9).
Of the two major T-cell subsets, CD8+ T-cells are known to be
the key effector cells that control viral infections via cytolytic activ-
ity and cytokine secretion. The importance of cytolytic function in
HCV infection is suggested by the fact that CD8+ T-cell responses
coincide not only with the decrease of HCV RNA titers in blood,
but also with the peak in serum alanine aminotransferase (ALT)
(10, 11), which is a marker of hepatocyte injury. Interferon-γ (IFN-
γ) secreted by CD8+ T-cells also directly exerts antiviral functions.
It was shown that IFN-γ suppresses viral replication in HCV repli-
con studies (12, 13). In addition, the antiviral functions of CD8+
T-cell-secreted IFN-γ were further demonstrated in cocultures of
HCV replicon cells and HCV-specific CD8+ T-cells (14).
In fact, the initial study on immune response in HCV-infected
chimpanzees showed that HCV-specific CD8+ T-cell response well
correlated with protection against HCV (15). The role of CD8+
T-cells in HCV infection was once clearly demonstrated by a chim-
panzee study with antibody-mediated depletion of CD8+ T-cells.
In this study, CD8+ T-cells were depleted prior to HCV challenge,
and viral load remained at high levels for a prolonged period with-
out CD8+ T-cells (16). Viral clearance was only achieved after
HCV-specific CD8+ T-cells recovered in the liver (16).
The importance of CD8+ T-cells in HCV infection is also
supported by immunogenetics studies that showed associations
between specific human leukocyte antigen (HLA) class I allo-
types and clinical outcome of HCV infection. HLA-B27, -B57,
and -A3 are known to be associated with a high rate of HCV
clearance (17–19).
In this review, we summarize various aspects of CD8+ T-cell
responses in acute HCV infection. In particular, we focus on tim-
ing of CD8+ T-cell responses, relationship between CD8+ T-cell
responses and outcomes of acute HCV infection, receptor expres-
sion on CD8+ T-cells, breadth of CD8+ T-cell responses, and viral
mutations.
CLINICAL COURSE OF ACUTE HCV INFECTION
In principle, acute HCV infection is defined as the first 6 months
following infection with HCV. Although HCV RNA titer is high
in the circulation, the majority of patients remain asymptomatic
during acute HCV infection with only 15% of infected patients
undergoing symptomatic acute hepatitis C (20). In addition, a
third of symptomatic infected patients do not produce detectable
anti-HCV antibodies at the onset of symptoms (21). Accordingly,
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it is difficult to identify patients with acute HCV infection and to
study immune responses during this period. Therefore, much of
the knowledge regarding T-cell responses in acute HCV infection
has been gleaned through studies of a chimpanzee model. Since
the initial study on CD8+ T-cells in chimpanzees with acute HCV
infection (15), monoclonal HCV infection of chimpanzees fur-
ther enabled precise analyses of CD8+ T-cells during acute HCV
infection (11, 22).
After inoculation of 100 chimpanzee infectious dose 50
(CID50) of monoclonal HCV-positive plasma, viral RNA becomes
detectable in serum within 1–2 weeks and increases rapidly there-
after (11). However, liver injury only increases minimally despite
a high level of viremia during this incubation phase, which lasts
about 8–12 weeks. During the incubation period, the expression
of IFN-stimulated genes (ISGs) is induced in the infected liver
(23). In terms of ISGs induction, HCV infection contrasts with
hepatitis B virus (HBV) infection. In fact, ISGs expression is not
induced by HBV infection (24), and thus HBV is considered a
stealth virus (25).
Serum ALT peaks at 8–12 weeks after HCV infection, and the
viral RNA titer begins to decrease at this time (11). Of interest,
there are three different patterns of viral RNA decrease as ini-
tially proposed by Thimme et al. (10). In the first pattern, HCV
RNA titer is decreased below the lower detection limit, and ulti-
mately HCV is cleared (Figure 1A). In the second pattern, HCV
RNA titer is decreased below the lower detection limit, but HCV
RNA reappears in the serum within several weeks and the infec-
tion evolves to a chronic persistent infection (Figure 1B). In the
third pattern, HCV RNA titer only undergoes a 2–3 log reduc-
tion and the infection evolves to a chronic persistent infection
(Figure 1C). Thus, HCV infection of chimpanzees with a single
molecular clone results in a relatively uniform course of acute
HCV infection with significantly divergent outcomes. Therefore,
several interesting immunological questions have arisen and have
been studied in this model as described below.
TIMING OF CD8+ T-CELL RESPONSES IN THE LIVER AND
BLOOD
Initially, a relatively late appearance of virus-specific T-cells in the
infected liver was described during acute HCV infection in a chim-
panzee study (10). Following infection, HCV replicates rapidly and
viral titers increase to high levels in the circulation within days
in a chimpanzee model (11, 26). However, HCV-specific T-cell
responses do not become detectable in the liver until 8–12 weeks
after infection (10). This delay of intrahepatic T-cell responses
was shown through functional assays using in vitro expanded,
liver-infiltrating T-cells (10). In addition, mRNA analyses showed
that the expression of CD8β and IFN-γ increases in the liver at 8–
12 weeks after infection (Figure 1D) (10, 11, 26, 27). Further, CD8β
and IFN-γ mRNA expression in the liver coincides with a decline
in viral titer (Figure 1D), even in the hosts with a chronically
evolving course of infection (28).
Recently, the underlying cause of the delayed intrahepatic T-cell
responses was revealed through study of HCV-infected chim-
panzees (29). In this study, appearance of HCV-specific CD8+
T-cells in the circulation was analyzed using major histocom-
patibility complex (MHC) class I tetramers. During acute HCV
infection, virus-specific CD8+ T-cells appear in the blood at late
FIGURE 1 | Virologic courses and kinetics of CD8+ T-cell responses in
acute HCV infection. (A–C) Three virologic patterns of acute HCV infection
(11). (D) Kinetics of CD8+ T-cell response in acute HCV infection (20, 21).
The frequency of HCV-specific CD8+ T-cells in the blood and mRNA levels of
CD8β and IFN-γ in the liver are presented. The appearance of HCV-specific
CD8+ T-cells in the blood coincides with the increase in mRNA levels of
CD8β and IFN-γ in the liver and with serum ALT elevation and a decrease in
HCV RNA titer.
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time points (8–12 weeks after HCV infection) and the appearance
of HCV-specific CD8+ T-cells in the blood coincided precisely
with the CD8+ T-cell infiltration to the liver, which was quantified
by assessing CD8β mRNA levels (Figure 1D) (29). Furthermore,
while HCV-specific CD8+ T-cells are induced at late time points,
T-cell-recruiting chemokines for CXCR3 and CCR5 are expressed
in the HCV-infected liver at early time points (2–8 weeks after
HCV infection) (29). Thus, intrahepatic chemokines recruit HCV-
specific CD8+ T-cells to the liver as soon as they appear in the
blood. Therefore, it can be concluded that the delay in intrahep-
atic T-cell responses is not due to delayed recruitment, but rather,
to delayed priming of HCV-specific CD8+ T-cells (29).
Thus, compared with other viral infections, HCV infection
is characterized by delayed induction of virus-specific CD8+ T-
cells. This delayed T-cell induction explains the long incubation
period prior to development of immune-mediated liver injury
(29). Moreover, it may explain why the rate of chronic evolution is
so high after HCV infection (10, 11); however, the underlying cause
of this delayed induction of HCV-specific CD8+ T-cells is not yet
understood. During viral infection, efficient priming of CD8+
T-cells depends on cell death of virus-infected cells and the gen-
eration of inflammatory milieu. Virus-specific CD8+ T-cells are
primed by cross presentation of viral antigens from virus-infected
dying cells (30). HCV is known to be non-cytopathic, therefore
it may not kill enough hepatocytes to release viral antigens and
may not cause sufficient inflammation to induce cross presenta-
tion to CD8+ naïve precursor T-cells. This possibility needs to be
investigated in further studies.
Figure 2 summarizes the sequence of major events in acute
HCV infection. T-cell-recruiting chemokines for CXCR3 and
CCR5 are produced in the liver 2–8 weeks after HCV infection.
However, HCV-specific CD8+ T-cells appear in the blood no ear-
lier than 8–12 weeks after infection. These cells express CXCR3
and/or CCR5 (29) and are immediately recruited to the liver. Intra-
hepatic infiltration of T-cells results in liver injury, manifested by
serum ALT elevation and a decrease in HCV RNA titer.
The course of acute HCV infection is modified after re-
infection of previously recovered chimpanzees. The duration of
the re-infection is substantially shorter than that of the primary
infection even after re-challenge with different HCV genotypes
(31, 32). In addition, HCV-specific T-cell responses in the blood
and liver are detected at much earlier time point after re-infection,
compared to the primary infection (33), indicating rapid recall
responses of HCV-specific memory T-cells. In a setting of re-
infection, the role of CD8+ T-cells was studied by antibody-
mediated depletion of CD8+ T-cells. Depletion of CD8+ T-cells
and subsequent HCV re-challenge resulted in prolonged viremia,
and viral clearance occurred when HCV-specific CD8+ T-cells
recovered in the liver (16).
In line with the re-infection studies, successful vaccination
shifts the timing of HCV-specific CD8+ T-cell responses earlier.
In a study of chimpanzees vaccinated with recombinant aden-
ovirus and DNA against HCV non-structural proteins, HCV RNA
was transiently detected and disappeared, and serum ALT was
also transiently increased (Figure 3A) (34). In these vaccinated
hosts, HCV-specific CD8+ T-cells were detectable in the circula-
tion after vaccination, and they were further expanded after HCV
FIGURE 2 | Sequence of events during HCV-specific CD8+ T-cell
responses in blood and liver throughout acute HCV infection.
FIGURE 3 | Virologic course and kinetics of CD8+ T-cell responses after
HCV challenge in successfully vaccinated hosts. (A) Virologic course
after HCV challenge in successfully vaccinated hosts (23). HCV RNA was
transiently detected and disappeared, and serum ATL was also transiently
elevated. (B) Kinetics of CD8+ T-cell responses after HCV challenge in
successfully vaccinated hosts (19, 24). Early CD8+ T-cell responses are
shown by the frequency of HCV-specific CD8+ T-cells in the blood and
mRNA levels of CD8β and IFN-γ in the liver.
challenge (35). As a result, the frequency of HCV-specific CD8+
T-cells in the vaccinated animals reached peak levels as early as
4 weeks after HCV challenge (Figure 3B), which was 7–15 weeks
earlier than in the mock-vaccinated control animals. Accordingly,
intrahepatic T-cell responses, evaluated by mRNA levels of CD8β
www.frontiersin.org June 2014 | Volume 5 | Article 266 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sung et al. CD8 responses in HCV infection
and IFN-γ, were much earlier in the vaccinated animals than in
the mock-vaccinated control animals (Figure 3B) (27).
HCV-SPECIFIC CD8+ T-CELL RESPONSES AND ACUTE HCV
INFECTION OUTCOMES
As described above, HCV-specific CD8+ T-cells are induced and
appear in the blood at 8–12 weeks after HCV infection and are
recruited to the liver at the same time. However, the delayed induc-
tion of HCV-specific CD8+ T-cells was observed irrespective of
the outcome of acute HCV infection (29). Instead, spontaneous
resolution of acute HCV infection correlates with robust and sus-
tained responses of HCV-specific T-cells in patients (6, 8, 36)
and chimpanzees (10, 15). In contrast, chronic evolution of acute
HCV infection is associated with weak and transient responses of
HCV-specific T-cells (8, 10, 15, 36). In addition, the appearance
of vigorous HCV-specific CD8+ T-cell responses against multiple
epitopes was associated with the onset of viral clearance (6, 8). In
a recent study of a chimpanzee model infected with monoclonal
HCV, a similar result was reported (37). In this study, HCV-specific
T-cell responses in the blood were comprehensively evaluated by
IFN-γ enzyme-linked immunosorbent spot (ELISpot) assays with
overlapping peptides covering all HCV proteins. While the HCV-
specific IFN-γ response was strong in the chimpanzees with a
self-limiting course of infection, it was undetectable or delayed in
the chimpanzees with a chronically evolving course of infection
(37). T-cell response was analyzed also in human immunode-
ficiency virus-positive patients with acute HCV infection, and
spontaneous clearance of acute HCV infection was associated with
strong T-cell response against HCV antigens (38).
Early antiviral therapy with pegylated IFN-α and ribavirin is
effective in patients with acute HCV infection, and thus it prevents
the development of chronic hepatitis. Then what will happen to
HCV-specific CD8+ T-cells during successful antiviral therapy in
patients with acute HCV infection? HCV-specific CD8+ T-cells
observed in the early acute phase of HCV infection are main-
tained by continuous stimulation with HCV antigens; therefore,
initiation of early antiviral therapy during acute HCV infection
results in a rapid decline in CD8+ T-cell responses (39, 40). This
finding implies that most HCV-specific CD8+ T-cells in the early
acute phase of HCV infection are short-lived and furthermore,
they are antigen-dependent effector cells rather than self-renewing
memory T-cells (40).
As described above, acute HCV infection is often asymptomatic
and induces mild inflammation in the liver. In rare cases, however,
acute HCV infection results in severe hepatitis, which is known
to be mediated by immune responses. In an interesting report
regarding two rare severe cases of acute HCV infection, vigorous
CD8+ T-cell responses were found to be narrowly focused against
HCV NS31073 peptide. Further, HCV NS31073-specific CD8+ T-
cells were cross-reactive with a peptide from influenza virus (41),
though it was shown later that this cross-reactivity is relatively
weak (42). It was inferred that influenza virus peptide-specific
CD8+ memory T-cells generated during the previous influenza
infection were vigorously activated due to cross-reactivity with
HCV and subsequently induced severe liver damage (43). One
striking feature of the clinical courses of these two patients was the
development chronic HCV infection after severe acute infection
in spite of the fact that they exhibited vigorous T-cell responses
(41). This finding suggests that the vigor of HCV-specific CD8+
T-cells is not the sole factor determining the outcome of acute
HCV infection.
RECEPTOR EXPRESSION ON HCV-SPECIFIC CD8+ T-CELLS
In chronic HCV infection, HCV-specific T-cells are function-
ally impaired, as evidenced by decreased proliferation, cytokine
production, and cytolytic activity (44, 45). This impaired func-
tion has been attributed to upregulation of inhibitory recep-
tors such as programed cell death-1 (PD-1) (46–53), cyto-
toxic T-lymphocyte-associated antigen 4 (CTLA-4) (47, 48), T-
cell immunoglobulin and mucin domain-containing molecule 3
(Tim-3) (49, 50), 2B4, CD160, and killer cell lectin-like receptor
G1 (KLRG1) (51). In chronically HCV-infected patients, HCV-
specific CD127loCD8+ T-cells co-expressed the inhibitory recep-
tors PD-1, 2B4, CD160, and KLRG1 (51), and their expression
was associated with the absence of viral escape mutations within
the corresponding epitopes, indicating that continuous anti-
genic stimulation is required for the expression of the inhibitory
receptors (51). In this report, HCV-specific CD127loCD8+ T-
cells could be partly, but not completely, restored function-
ally by PD-1 blockade alone, suggesting the role of multiple
inhibitory receptors in T-cell dysfunction during chronic HCV
infection (51).
However, the expression and role of inhibitory receptors has
been controversial in acute HCV infection. Initially, high levels of
PD-1 on HCV-specific T-cells and PD-1 mRNA in the liver were
reported in patients (54) and chimpanzees (55) with acute HCV
infection that later progressed to chronic persistent infection. In
contrast, other studies showed that PD-1 expression is high on
HCV-specific T-cells in acute HCV infection irrespective of the
outcome of infection (56, 57). A recent study focused on this issue
using chimpanzees acutely infected with monoclonal HCV (37).
In this study, the PD-1 level on HCV-specific CD8+ T-cells peaked
after appearance of HCV-specific CD8+ T-cells in the blood and
decreased thereafter irrespective of the outcome of infection. In
addition, intrahepatic mRNA levels of inhibitory receptor genes
did not differ among chimpanzees with divergent outcomes of
infection. Moreover, upregulation of PD-1 on HCV-specific CD8+
T-cells during acute HCV infection did not interfere with HCV
clearance in spontaneously recovered hosts. Thus, following func-
tional analyses of HCV-specific CD8+ T-cells, it was proposed that
PD-1 is an activation marker, rather than an exhaustion marker,
in acute HCV infection. This is consistent with the fact that PD-1
expression can be transiently induced by T-cell receptor and/or
cytokine stimulation (58, 59).
In contrast to naïve chimpanzees, vaccinated chimpanzees have
a different expression profile of PD-1 during acute HCV infec-
tion. In a study of chimpanzees vaccinated with recombinant
adenovirus and DNA against HCV non-structural proteins, HCV-
specific CD8+ T-cells in vaccinated animals displayed lower levels
of PD-1 than those in the mock-vaccinated control animals (35).
It was interpreted that early control of viremia by vaccine-induced
T-cells prevented upregulation of PD-1 on HCV-specific CD8+
T-cells. Hence, the low expression of PD-1 might be an indica-
tor of early viral control in vaccinated hosts (35). Taken together,
it seems that the functional significance of PD-1 expression on
virus-specific CD8+ T-cells differs between acute and chronic
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HCV infections, and between HCV infections with or without
vaccination.
Interestingly, the outcome of acute HCV infection was related
to the expression of CD127, also known as IL-7Rα, a marker of
memory precursor cells (60). Indeed, a high frequency of CD127+
cells among HCV-specific CD8+ T-cells was observed in hosts
that subsequently cleared the acute infection even when virus had
been detectable in the blood. However, the frequency of CD127+
cells was low in hosts with chronically evolving infection. This
is consistent with the fact that CD127 expression is decreased
on HCV-specific T-cells in patients who were studied late in the
course of acute HCV infection (9, 51, 61–63). Taken together,
the frequency of HCV-specific CD127+CD8+ T-cells predicts the
outcome of acute HCV infection when hosts are still viremic (37).
BREADTH OF CD8+ T-CELL RESPONSES AND VIRAL
MUTATION
The breadth of CD8+ T-cell responses is an important factor
in viral clearance during acute HCV infection (6, 64). Multiple
epitopes-specific CD8+ T-cell responses contribute to viral clear-
ance by suppressing the emergence of viral mutations. In fact,
HCV-specific CD8+ T-cell responses are narrow over the chroni-
cally evolving course of acute HCV infection (6, 65). In contrast, a
prospective study with chimpanzees showed that the animals with
self-limited acute HCV infection exhibited CD8+ T-cell responses
against multiple epitopes (10). During acute HCV infection, the
broadest CD8+ T-cell responses occur during the early phase with
a subsequent decline in the breadth of response (64, 66). For exam-
ple, in a longitudinal study of acutely infected injection drug users,
patients with progression to chronic infection lost recognition of
one or more T-cell epitopes recognized during acute infection (64).
Acute HCV infection progresses to a chronic persistent infec-
tion if rapidly generated viral mutations overwhelm and outpace
the CD8+ T-cell response. In the initial study with HCV-infected
chimpanzees, it was demonstrated that the emergence of viral
escape mutants in CD8+ T-cell epitopes correlated with viral per-
sistence (67). A more recent study defined escape mutations in
multiple CD8+ T-cell epitopes in patients that developed chronic
infection. In this study, patients that cleared HCV had no sub-
stitutions within any recognized T-cell epitopes after the initial
viremia (68).
During acute HCV infection, virus evolution is driven pri-
marily by positive selection pressure exerted by CD8+ T-cells.
This influence of immune pressure on viral evolution appears
to subside as chronic infection is established (69). Recently, it
was reported that the immunoregulatory changes of pregnancy
reduce the selective pressure of HCV-specific CD8+ T-cells on T-
cell epitopes, thereby facilitating vertical transmission of viruses
with optimized replicative fitness (70). Thus, a strong CD8+ T-cell
response eradicates HCV infection and a weak response will cause
few mutations with optimized replication fitness. An intermediate
immune response, which is usually the case, can stress the virus
and select for escape mutants, resulting in viral persistence and a
broader viral quasispecies (71).
CONCLUSION
In this review, we have summarized various aspects of CD8+ T-
cell responses in acute HCV infection. Acute HCV infection is
characterized by delayed induction of virus-specific CD8+ T-cells,
which cause the late onset of inflammation and viral control. In
acute HCV infection, the expression of inhibitory receptors such
as PD-1 is not related to T-cell exhaustion, while the expression of
CD127 predicts the outcome of infection. In addition, the strength
and breadth of HCV-specific CD8+ T-cell responses are associated
with the outcome of acute HCV infection.
In previous studies, the nature of HCV-specific CD8+ T-cells
has been examined using T-cells obtained from patients or chim-
panzees with HCV infection. However, HCV-infected cells also
need to be studied in the context of interaction between effec-
tor CD8+ T-cells and target cells. In particular, the regulation
of the antigen processing and presentation machineries in HCV-
infected cells is of interest, including immunoproteasomes (28),
proteasome activators (72), and MHC molecules. In fact, a recent
study demonstrated that HCV attenuates IFN-induced expression
of MHC class I molecules, which are required for the recognition
of virus-infected cells by CD8+ T-cells. This was suggested as a
mechanism of evasion from antiviral CD8+ T-cell responses (73).
Currently, T-cell vaccines against HCV infection are now being
developed. In particular, a result of phase I study on recombi-
nant adenoviral vector-based vaccines was recently reported (74).
Adenoviral vectors expressing non-structural proteins induced
T-cell responses against multiple HCV proteins, and vaccine-
induced T-cells recognized heterologous strains. Moreover, they
were polyfunctional and sustained for a prolonged period (74).
These vaccine candidates might be useful for both prophylactic
and therapeutic purposes.
In conclusion, spontaneous recovery from acute HCV infec-
tion is associated with effective CD8+ T-cell responses. In contrast,
progression to chronic persistent infection is associated with the
impaired function of CD8+ T-cells and immune-evading viral
mutations. Therefore, the induction of early and robust CD8+ T-
cell responses will be a focus for development of successful HCV
vaccines in the future.
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